

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Equality impact assessment

IPG593 Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

Scoping

| |
|---|
| <p>1. Have any potential equality issues been identified during the scoping process (development of the scope or discussion at the Committee meeting), and, if so, what are they?</p> |
| <p>Amyotrophic lateral sclerosis (ALS) is another neurodegenerative disease causing respiratory failure and requires mechanical ventilation. In the UK, about 2 in 100,000 develop this disease each year and currently there are about 5000 people with this problem.</p> <p>ALS is rare under the age of 40 years but usually develops between 50 and 70 years. It is twice as common in men as in women.</p> <p>Patients with ALS/MND are likely to be covered under disability under the Equality Act 2010 as their condition has a substantial adverse effect on activities of daily living that have lasted longer than 12 months or are likely to do so.</p> |
| <p>2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? If there are exclusions listed in the scope (for example, populations, treatments or settings), are these justified?</p> |
| <p>This was not thought to have an impact on the assessment of the procedure. No exclusions were applied.</p> |

| |
|--|
| 3. Has any change to the scope (such as additional issues raised during the Committee meeting) been agreed to highlight potential equality issues? |
| No |

| |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the committee meeting, and, if so, have changes to the stakeholder list been made? |
| No |

Kevin Harris

Approved by Programme Director and Clinical Advisor

Date: 01/08/2017

Consultation

| |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
| Not applicable. |

| |
|--|
| 2. Have any other potential equality issues been raised in the overview, specialist adviser questionnaires or patient commentary, and, if so, how has the Committee addressed these? |
| No |

| |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
| No |

| |
|---|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group? |
| Not applicable |

| |
|---|
| 5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| Not applicable |

| |
|---|
| 6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligation to promote equality? |
| Not applicable |

| |
|---|
| 7. Have the Committee's considerations of equality issues been described in the consultation document, and, if so, where? |
| Not applicable |

Kevin Harris

Approved by Programme Director and Clinical Advisor

Date: 01/08/2017

Final interventional procedures document

| |
|--|
| 1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these? |
| Not applicable |

| |
|---|
| 2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group? |
| Not applicable |

| |
|--|
| 3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality? |
| Not applicable |

| |
|--|
| 4. Have the Committee's considerations of equality issues been described in the final interventional procedures document, and, if so, where? |
| Not applicable |

Mirella Marlow

Approved by Programme Director

Date: 29 August 2017